Floatz logo

Palifosfamide-Tris

Extensive-Stage Small Cell Lung Cancer

Alaunos TherapeuticsPhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

291 Active assets in the Extensive-Stage Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Palifosfamide-Tris is also rated in:

breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
adult central nervous system germ cell tumorDormant
CCC
Indicative ·
48 / 100
View asset →
adult teratomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →